| 名稱 | AZD2858 |
| 描述 | AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway. |
| 細胞實驗 | Human adipose derived stem cells and rat MSCs (isolated from bone marrow of Sprague Dawley rats at less than 8 weeks after gestation) are cultured in a basal media of DMEM containing 5% FBS and 2 mM GlutaMax. Cells are seeded in basal media into 96-well plates (3–5000 cells/well) for 18 h before treatment with AZD2858 (0.3 nM to 20 mM). After 24 h, β-catenin stabilisation is measured.(Only for Reference) |
| 激酶實驗 | Tau phosphorylation assay: NIH-3T3 cells expressing 4-repeat Tau are used to assess functional activity of AZD2858 in vitro. The cells are grown in DMEM media and 2 mM L-glut, and 10% HiFCS, and plated at a concentration of 6×105 cells/well in 6-well plates. In each experiment, AZD2858 is dosed in triplicates at a concentration of 1, 10, 100, 500, 1000, 2000 and 10,000 nM. Cells are treated for 4 h prior to cell lysis using 100 μL ice cold lysis buffer (0.5% NP-40, 10 mM Tris, pH 7.2, 150 mM NaCl, 2 mM EDTA). A suspension is made with addition of protease and phosphatase inhibitors: 50 mM NaF, 0.2 mM NaVO4 and Cocktail Protease inhibitors. The solution is then snap frozen at ? 80 °C for at least 1 h, before thawing on ice and lysate clarification by centrifugation, followed by Western blot according to standard protocols. After blocking, the blots are exposed to the primary antibody, Phospho-Ser396-tau (1:1000) over night, washed and incubated with the secondary antibody (donkey anti-rabbit, 1:5000), followed by a final wash. For re-probing, the primary antibody Tau5 (1:200) and the secondary horseradish peroxidase linked antibody (sheep anti-mouse, 1:10000) are used. All blots are developed using ECL Western blot detection reagents, Kodak X-ray films, quantified using densitometric analysis, and the ratio of S396 tau to total tau (tau5) is calculated. |
| 體外活性 | 30 μM/kg AZD2858處理大鼠三周后胼胝中礦物質(zhì)密度(2周時28%,三周時38%)和礦物質(zhì)含量(兩周時81%,三周時93%)增加.大鼠用AZD2858處理28天后,血清中骨更新標志物產(chǎn)生時間依賴性變化,且骨密度增加.大鼠用AZD2858處理7天后,骨形成標志P1NP增加,溶蝕標志物TRAcP-5b降低,表明骨合成代謝增加,大鼠吸收減少.大鼠口服AZD2858治療兩周后,與對照組相比,引起骨密度劑量依賴增加,治療兩周后,在每天20 mg/kg(總BMC: 對照組的172%)劑量下具有最大療效.AZD2858處理使骨折恢復(fù)更快,有骨性骨痂但沒有明顯的軟骨成分. |
| 體內(nèi)活性 | AZD2858在人類和大鼠間充質(zhì)干細胞中引起β-連環(huán)蛋白穩(wěn)定,激活體外成骨細胞和成骨礦化。初級分離的人成骨細胞樣細胞上AZD2858處理（1 μM,12小時）導(dǎo)致β-連環(huán)蛋白水平增加3倍。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 7 mg/mL (15.43 mM)
|
| 關(guān)鍵字 | AZD-2858 | Glycogen synthase kinase 3 | GSK-3 | Glycogen synthase kinase-3 | inhibit | Inhibitor | AZD2858 | AZD 2858 |
| 相關(guān)產(chǎn)品 | Cromolyn sodium | Ginsenoside Rg2 | 4-Chloro-2'-bromoacetophenone | CHIR-99021 HCl | AT7519 | 5-Bromoindole | GSK-3 Inhibitor 5 | GSK 3 Inhibitor IX | SNS-032 | Cyanoacetohydrazide | CHIR-99021 | 1-Azakenpaullone |
| 相關(guān)庫 | 抑制劑庫 | 神經(jīng)保護化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | 抗肥胖化合物庫 | 糖代謝化合物庫 | 神經(jīng)退行性疾病化合物庫 | 口服活性化合物庫 |